AIM: Bisphosphonates have been shown to induce ocular inflammatory diseases such as uveitis and scleritis, while being protective against angiogenic diseases like neovascular age-related macular degeneration (AMD). Therefore, we studied the effects of bisphosphonates on primary culture of human fetal retinal pigment epithelium (hRPE), a cell type known to secrete both inflammatory and angiogenic factors. Alendronate and etidronate were selected for this experiment as they are members of the two structurally different classes of bisphosphonates. METHODS: Primary cultures of hRPE were serum-starved for 24 h and then treated for 24 h with alendronate (0.0001, 0.1, 100 µM) or etidronate (0.01, 1 µM). Cell viability was measured using the MTT assay. Investigation of secreted cytokines induced by bisphosphonates was performed using a human cytokine 29-Plex Panel (Bio-Plex) array and the results were analysed with an analysis of variance (ANOVA). RESULTS: Etidronate, at the lower concentration, significantly increased the expression of interleukin (IL)-6 (p=0.03) and IL-8 (p=0.04). At the higher concentration, etidronate significantly decreased the expression of granulocyte macrophage colony-stimulating factor (p=0.02) and basic fibroblast growth factor (bFGF) (p=0.02). Alendronate, at the highest concentration, significantly increased the expression of IL-8 (p=0.02) and decreased the expression of eotaxin (p=0.02). Alendronate also significantly decreased the expression of bFGF at all concentrations (p<0.05) and demonstrated a trend towards decreasing vascular endothelial growth factor expression at low concentration. CONCLUSIONS: Alendronate and etidronate display dose dependent effects in hRPE cells. Alendronate and etidronate administration resulted in concentration dependent elevations in inflammatory cytokines. Furthermore, alendronate and etidronate administration resulted in reduced expression of a number of angiogenic factors. These findings may explain the increased incidence of ocular inflammation as well as the therapeutic effect on neovascular AMD which have been described with bisphosphonates.
AIM: Bisphosphonates have been shown to induce ocular inflammatory diseases such as uveitis and scleritis, while being protective against angiogenic diseases like neovascular age-related macular degeneration (AMD). Therefore, we studied the effects of bisphosphonates on primary culture of human fetal retinal pigment epithelium (hRPE), a cell type known to secrete both inflammatory and angiogenic factors. Alendronate and etidronate were selected for this experiment as they are members of the two structurally different classes of bisphosphonates. METHODS: Primary cultures of hRPE were serum-starved for 24 h and then treated for 24 h with alendronate (0.0001, 0.1, 100 µM) or etidronate (0.01, 1 µM). Cell viability was measured using the MTT assay. Investigation of secreted cytokines induced by bisphosphonates was performed using a human cytokine 29-Plex Panel (Bio-Plex) array and the results were analysed with an analysis of variance (ANOVA). RESULTS:Etidronate, at the lower concentration, significantly increased the expression of interleukin (IL)-6 (p=0.03) and IL-8 (p=0.04). At the higher concentration, etidronate significantly decreased the expression of granulocyte macrophage colony-stimulating factor (p=0.02) and basic fibroblast growth factor (bFGF) (p=0.02). Alendronate, at the highest concentration, significantly increased the expression of IL-8 (p=0.02) and decreased the expression of eotaxin (p=0.02). Alendronate also significantly decreased the expression of bFGF at all concentrations (p<0.05) and demonstrated a trend towards decreasing vascular endothelial growth factor expression at low concentration. CONCLUSIONS:Alendronate and etidronate display dose dependent effects in hRPE cells. Alendronate and etidronate administration resulted in concentration dependent elevations in inflammatory cytokines. Furthermore, alendronate and etidronate administration resulted in reduced expression of a number of angiogenic factors. These findings may explain the increased incidence of ocular inflammation as well as the therapeutic effect on neovascular AMD which have been described with bisphosphonates.
Authors: D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum Journal: Am J Ophthalmol Date: 2000-10 Impact factor: 5.258
Authors: Victor L Perez; George N Papaliodis; David Chu; Fahd Anzaar; William Christen; C Stephen Foster Journal: Ocul Immunol Inflamm Date: 2004-09 Impact factor: 3.070
Authors: Ahjoku Amadi-Obi; Cheng-Rong Yu; Xuebin Liu; Rashid M Mahdi; Grace Levy Clarke; Robert B Nussenblatt; Igal Gery; Yun Sang Lee; Charles E Egwuagu Journal: Nat Med Date: 2007-05-13 Impact factor: 53.440
Authors: A P Adamis; D T Shima; K T Yeo; T K Yeo; L F Brown; B Berse; P A D'Amore; J Folkman Journal: Biochem Biophys Res Commun Date: 1993-06-15 Impact factor: 3.575
Authors: Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez Journal: Methods Mol Biol Date: 2021
Authors: Cesar Garriga; Michael Pazianas; Samuel Hawley; Antonella Delmestri; Daniel Prieto-Alhambra; Cyrus Cooper; Andrew Judge Journal: Ann N Y Acad Sci Date: 2018-01-24 Impact factor: 5.691
Authors: Muhammad Hassan; Arash Maleki; Qian Ying; Nam Nguyen; Muhammad Sohail Halim; Yasir J Sepah; Diana V Do; Quan Dong Nguyen Journal: Am J Ophthalmol Case Rep Date: 2019-01-09
Authors: Sara Risseeuw; Redmer van Leeuwen; Saskia M Imhof; Pim A de Jong; Willem P Th M Mali; Wilko Spiering; Jeannette Ossewaarde-van Norel Journal: PLoS One Date: 2020-10-20 Impact factor: 3.240
Authors: Jocelyne Mulangala; Emma J Akers; Emma L Solly; Panashe M Bamhare; Laura A Wilsdon; Nathan K P Wong; Joanne T M Tan; Christina A Bursill; Stephen J Nicholls; Belinda A Di Bartolo Journal: Int J Mol Sci Date: 2022-03-20 Impact factor: 5.923